British American TobaccoBATS
BATS logo
Fair Value
UK£51.5
Share price16 Aug
UK£42.1418.2% undervalued intrinsic discount
Loading
1Y-1.08%
7D-0.33%

Emerging Markets And Digital Transformation Will Enable Long-Term Stability

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
23 Feb 25
Updated
16 Aug 26
Views
1.2k
Not Invested

Last Update 16 Aug 26

Fair value Increased 2.44%

BATS: AI Technology Partnership And Buybacks Will Support Future Returns

The analyst price target for British American Tobacco has been revised from £50.27 to £51.50, with analysts citing updated assumptions for discount rate, revenue growth, profit margin and future P/E to support the new view.

What’s in the News for British American Tobacco

  • ITC Infotech expanded its multi year technology partnership with British American Tobacco to support AI driven transformation of the company’s technology systems across Poland, Romania, India, Malaysia and Mexico, building on an existing relationship. Source: ITC Infotech and company announcement.
  • The collaboration with ITC Infotech includes scaling capabilities at British American Tobacco’s Future Capabilities Centre in India and aims to streamline end to end technology delivery to improve speed, efficiency and service quality across multiple regions. Source: ITC Infotech and company announcement.
  • British American Tobacco and Philip Morris International, along with their Brazilian subsidiaries, are defendants in an ongoing lawsuit filed by Brazil’s Office of the Attorney General that seeks compensation for public health costs linked to tobacco use, with all legal submissions complete and the case awaiting a court decision in Porto Alegre. Source: Lawsuits and Legal Issues filing.
  • British American Tobacco updated its earnings guidance for the 2026 fiscal year. Full year EPS growth is now expected to be towards the middle of a 5% to 8% range. Revenue and operating profit are expected at the lower end of the previously indicated range, including an estimated 1% transactional FX headwind. Source: Corporate Guidance announcement.
  • The company reported that between 1 January 2026 and 30 June 2026 it repurchased 14,609,571 shares for £649m, bringing total repurchases under the buyback announced on 18 March 2024 to 72,236,980 shares, or 3.28% of the company, for £2,446.85m. Source: Buyback Tranche Update.

Valuation Changes for British American Tobacco

  • Fair Value has risen slightly from £50.27 to £51.50, reflecting modestly updated assumptions in the model.
  • Discount Rate has risen slightly from 8.68% to 9.02%, which points to a marginally higher required return in the updated analysis.
  • Revenue Growth assumption has risen slightly from 3.24% to 3.56%, which adjusts the outlook for future £ revenue expansion used in the valuation.
  • Net Profit Margin assumption has risen slightly from 29.52% to 30.45%, affecting projected £ earnings used in the cash flow forecasts.
  • Future P/E has remained effectively unchanged, moving fractionally from 16.38x to 16.38x in the updated framework.
0 viewsusers have viewed this narrative update

Key Takeaways

  • Expansion of reduced-risk products and innovation in emerging markets supports global growth, margin improvement, and earnings resilience.
  • Digital transformation and cost efficiency drive capital allocation, cash generation, and sustained shareholder returns.
  • Regulatory, market, and societal pressures threaten revenue stability, margin growth, and long-term business sustainability as BAT transitions from traditional cigarettes to newer product categories.

Catalysts

About British American Tobacco
    Provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States.
What are the underlying business or industry changes driving this perspective?
  • The rapid growth and further penetration of Modern Oral (Velo) and Heated Products, especially in emerging markets with rising disposable incomes, positions BAT well to tap into geographic revenue diversification and stabilize global volumes, supporting top-line growth in the medium to long term.
  • Strong uptake and premiumization of reduced-risk new category products (Modern Oral, Heated, and Vapour), combined with successful innovation rollouts (Velo Plus, glo Hilo, Vuse Ultra), are driving higher contribution margins and gross margins, setting the stage for structural net margin and earnings expansion as these products scale.
  • Digital transformation, operational streamlining, and targeted cost savings programs (e.g., Fit2Win, global supply chain efficiencies) are releasing capital for reinvestment in high-return growth opportunities and innovation, protecting operating margins and supporting future free cash flow growth.
  • Proactive adaptation to evolving regulatory environments (e.g., greater enforcement on illicit vapour, prioritizing science-backed engagement) and strategic resource allocation to profitable/favorable markets underpin management's ability to safeguard market share and drive resilience in both existing and new product segments, with the expected effect of stabilizing earnings.
  • Ongoing strong cash generation, disciplined deleveraging, and a commitment to progressive dividends and share buybacks enhance total shareholder return potential and underpin long-term financial flexibility, likely supporting sustained EPS growth and valuation re-rating as execution continues.
British American Tobacco Earnings and Revenue Growth

British American Tobacco Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming British American Tobacco's revenue will grow by 3.6% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 24.6% today to 30.4% in 3 years time.
  • Analysts expect earnings to reach £8.7 billion (and earnings per share of £4.16) by about August 2029, up from £6.3 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as £7.6 billion.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 16.4x on those 2029 earnings, up from 14.3x today. This future PE is greater than the current PE for the US Tobacco industry at 12.9x.
  • Analysts expect the number of shares outstanding to decline by 0.38% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 9.02%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Escalating regulatory risk and fiscal headwinds in key markets-such as flavor bans, strict enforcement inconsistency, and increased excise taxes (e.g., Bangladesh, Australia, Canada, and Malaysia)-continue to impact legal product availability and sales, particularly in vapour, which could erode BAT's revenues and operating margins over time.
  • Persistent illicit trade in vapour and combustible products, especially in the U.S. and Canada, undermines BAT's legal market share and limits its ability to grow volumes and revenues from both traditional and new category products, thereby putting pressure on revenue growth and earnings stability.
  • Ongoing secular declines in combustible cigarette volumes, despite near-term stabilization and pricing offsets, represent a fundamental risk to BAT's main revenue base (still >70% from combustibles), potentially leading to long-term revenue contraction and margin pressure as regulatory and public health pressure increases.
  • High and rising investment in new categories (Modern Oral, Heated, Vape) is required to offset declines in traditional products, yet these segments face intense competition, evolving regulatory hurdles, and inconsistent execution-risking lower-than-expected returns on investment, reduced profitability, and more volatile earnings.
  • ESG-related investor aversion and growing health consciousness may limit BAT's access to certain pools of institutional capital, suppress share valuations, and shrink the overall addressable market over the longer term, affecting both net margins and enterprise value.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of £51.5 for British American Tobacco based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of £57.5, and the most bearish reporting a price target of just £38.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be £28.6 billion, earnings will come to £8.7 billion, and it would be trading on a PE ratio of 16.4x, assuming you use a discount rate of 9.0%.
  • Given the current share price of £42.14, the analyst price target of £51.5 is 18.2% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on British American Tobacco?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Comments

0 comments

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

UK£39.51
FV
6.7% overvalued intrinsic discount
2.73%
Revenue growth p.a.
396
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative

Fair Value vs Share Price

UK£51.5
vs UK£42.1418.2% undervalued intrinsic discount
PastFuture-5b29b2015201820212024202620272029Revenue UK£28.6bEarnings UK£8.7b
3.6%
Revenue growth
30.4%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on British American Tobacco

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Undervalued established dividend payer.

Market capUK£90.9b
PB1.9x
Estimated Growth3.5%
Dividend Yield5.8%
Full analysis

CEO & management

Tadeu Marroco
CEO
3.9yrs
CEO Tenure

Provides tobacco and nicotine products to consumers in the United States, Europe, Latin America, Canada, the Asia-Pacific, the Middle East, Central Asia, Caucasus, and Africa.